DNA RNA and Cells

09 Sep 2020 NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
08 Sep 2020 Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors
08 Sep 2020 Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy
05 Sep 2020 Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta® in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
02 Sep 2020 Highlight Therapeutics Announces Second Phase II Oncology Collaboration with Merck
01 Sep 2020 Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19
01 Sep 2020 MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT
31 Aug 2020 GSK presents promising phase 2a data for chronic hepatitis B treatment
30 Aug 2020 Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
30 Aug 2020 Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
30 Aug 2020 bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data, at the 46th Annual Meeting of the EBMT
29 Aug 2020 Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients
28 Aug 2020 Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
26 Aug 2020 Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
25 Aug 2020 REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
25 Aug 2020 Expression Therapeutics Announces Success in Developing a Stem Cell Lentiviral Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH)
24 Aug 2020 RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines
21 Aug 2020 Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-linked Myotubular Myopathy
20 Aug 2020 CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR-T Cells
19 Aug 2020 BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
19 Aug 2020 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-125 by Intravitreal Injection for the Treatment of X-Linked Retinitis Pigmentosa
18 Aug 2020 Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
18 Aug 2020 Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors
18 Aug 2020 Aligos Therapeutics Doses First Subject in Phase 1 Proof of Concept Study of Oligonucleotide Drug Candidate ALG-010133
18 Aug 2020 Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up